Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: saquinavir Clear all
Completed Phase 2 Interventional

A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine

NCT00002333
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
41
States / cities
Harbor City, California • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 1 Interventional

A Study of 141W94 in Combination With Other Anti-HIV Drugs

NCT00002372
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Amprenavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 7:26 PM EDT
Completed No phase listed Observational

IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

NCT01232361
View directory record Official record
Conditions
ADHD, HIV
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 25 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 2 Interventional

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

NCT00002184
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 1 Interventional

Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients

NCT00000906
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Saquinavir, Methadone hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

NCT00039741
View directory record Official record
Conditions
HIV Infections
Interventions
NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
30 Days to 18 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
29
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 2 Interventional

A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

NCT00102206
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Emtricitabine, Lamivudine, Lopinavir/ritonavir, Saquinavir, Tenofovir disoproxil fumarate, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Stony Brook, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection

NCT00002347
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Nevirapine, Zidovudine, Zalcitabine
Drug
Lead sponsor
Parexel
Industry
Eligibility
13 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

NCT00001108
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 22 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Not applicable Interventional

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

NCT00051831
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine, Enfuvirtide, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 2 Interventional

Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC

NCT00001040
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Zidovudine, Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

NCT01252940
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TDF, PI, RTV, NRTIs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 1Phase 2 Interventional

Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV

NCT00084058
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
13
States / cities
Birmingham, Alabama • Long Beach, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 4 Interventional

The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs

NCT00002425
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 2 Interventional

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

NCT00000918
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Amprenavir, Efavirenz, Saquinavir, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 3 Interventional

A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

NCT00002382
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 7:26 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

NCT05502341
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
40
States / cities
Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

NCT00005762
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Amprenavir, Nelfinavir mesylate, Efavirenz, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
8
States / cities
Palo Alto, California • Aurora, Colorado • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 7:26 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT02016924
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 2 Interventional

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

NCT00000912
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
44
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 2 Interventional

Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects

NCT00043953
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Saquinavir mesylate, Lamivudine/zidovudine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2007 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 1 Interventional

A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.

NCT00002111
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 4 Interventional

Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients

NCT00002229
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
20
States / cities
Hobson City, Alabama • Phoenix, Arizona • Paramount, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 7:26 PM EDT
Completed Phase 3 Interventional

A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

NCT00002178
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 7:26 PM EDT